SCP-883
Euclid
~
medium confidence
SCP-883
Expected annual
$3.7M
One-time setup
$5.9M
Annual recurring
$3.7M
Personnel
23
Initial capital/setup costs are approximately $5.9M driven by lab buildout, antivenom research, secure infrastructure, communications and robotics; annual recurring costs are approximately $3.66M driven primarily by personnel (security and scientific staff) and ongoing research/monitoring.
One-Time Capital Costs
Total: $5.9M
Annual Recurring Costs
Total: $3.7M/yr
Cost Scenarios
📊
Baseline
(baseline)
$3.7M/yr
Normal year with ongoing operations, routine research and no major incidents.
routine operations
scheduled mapping and lab analysis
🚨
Minor Incident
$3.9M/yr
Small containment incident (injury, limited contamination) requiring medical evacuation, cleanup and limited equipment replacement.
individual severe sting or poisoning
small localized contamination event
minor equipment loss during mapping
🚨
Major Breach
$5.2M/yr
Major containment breach requiring large-scale eradication/neutralization attempts, contractor mobilization, extensive legal/PR and emergency research action.
large-scale hive escape or environmental contamination
multiple severe injuries or public exposure
Personnel
23 total
| Role | Count | Notes |
|---|---|---|
| Security Officer / MTF Agent | 12 | [#3] 24/7 on-site guards (three shifts) to enforce access, escort personnel and secure perimeter. |
| Research Scientist | 6 | [#4] Core scientific team (entomology, toxicology, chemistry, robotics/field techs) for research, mapping and analysis. |
| Medical Officer / Nurses | 3 | [#5] Onsite or on-call ER physician and nurses trained in envenomation and arsenic poisoning; includes medical support staff. |
| Site Director / Executive Staff | 1 | [#29] Program director/lead responsible for oversight, authorizations and liaison with Foundation command. |
| Administrative Staff | 1 | [#29] Administrative/procurement/accounting support for the containment program. |
Confidence Notes
Analyst notes provide detailed line items and ranges allowing a reasoned midpoint estimate, but many items (antivenom R&D, breach severity, interior unknowns) are highly uncertain and could change multi-year costs substantially.